Premium

Wockhardt to exit US generic pharma segment, shut down 2 subsidiaries

Over the past several years, Wockhardt’s US generics business has been incurring losses, it said.

Wockhardt is undertaking significant strategic realignment of its US business in line with its long-term vision to build a differentiated, innovation-driven pharmaceutical enterprise, it said. (Source: Wikimedia Commons)

Amid the ongoing trade tariff related concerns, Indian pharmaceutical firm Wockhardt Ltd on Friday said it has decided to exit the US generic pharmaceutical segment, paving the way for deeper focus and investment in its advanced product portfolio.

Over the past several years, Wockhardt’s US generics business has been incurring losses, it said. In FY 2025 alone, the generics business incurred a loss of nearly US $ 8 million, it said. “Following a comprehensive strategic review, the company has concluded that continuing in this segment would detract from its broader innovation agenda,” the company said in an exchange filing.

Accordingly, Wockhardt has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its US step-down subsidiaries, Morton Grove Pharmaceuticals Inc and Wockhardt USA LLC, both incorporated in Delaware which are wholly owned subsidiaries of Wockhardt Bio AG. This decision, effective July 11, 2025, enables a clean and structured exit from a legacy segment and unlocks management bandwidth and capital for high-impact areas, the company said.

Story continues below this ad

Wockhardt is undertaking significant strategic realignment of its US business in line with its long-term vision to build a differentiated, innovation-driven pharmaceutical enterprise, it said.

This strategic reset aligns with Wockhardt’s sharpened focus on building a future-ready business anchored in two key pillars: New antibiotic drug discovery – where Wockhardt has established a leadership position globally, with a strong pipeline of differentiated assets; Biologicals portfolio in insulin – leveraging advanced technologies to address critical unmet needs in diabetes care.

“By stepping away from the commoditized generics space, Wockhardt is positioning itself to create long-term value through innovation, scientific excellence, and sustainable profitability,” it said.

“The company remains committed to its pharmaceutical operations in India, the UK, Ireland, and other geographies where its businesses continue to deliver strong performance,” it said. This strategic evolution marks a decisive move toward a more focused, resilient, and innovation-led Wockhardt, better equipped to deliver value to patients, partners, and shareholders in the years ahead, it said.

Men who opened fire outside actor Disha Patani’s home killed in encounter in Ghaziabad

Cities4 hr ago

Two men belonging to the Rohit Godara-Goldy Brar Gang were killed in an encounter in Ghaziabad, suspected to be involved in the firing outside Disha Patani's residence. The duo, identified as Ravindra and Arun, were wanted in multiple cases and were spotted by the police through CCTV footage. UP CM Yogi Adityanath had directed for a speedy investigation and strict action against the perpetrators.

View all shorts

Live Blog